The collaboration will provide urologists and oncologists nationwide access to AI-powered tools for non-muscle invasive bladder cancer management.
Valar Labs has formed a strategic partnership with PathNet Lab to deliver AI-driven bladder cancer diagnostic tools through PathNet’s national laboratory network.
The collaboration will provide clinicians access to Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict, both part of Valar Labs’ AI-powered diagnostic portfolio for non-muscle invasive bladder cancer (NMIBC). The tools are designed to help urologists and oncologists incorporate AI-driven prognostic and predictive insights into clinical decision-making.
“PathNet has established itself as a national leader and a trusted diagnostic partner for many of the country’s largest urology groups,” says Anirudh Joshi, CEO of Valar Labs, in a release. “They are [an] ideal partner to expand access to Vesta tests to urology practices nationally. Together, we can deliver more confident, personalized treatment guidance to patients across diverse care settings.”
Digital Pathology Infrastructure
PathNet operates as a digital pathology laboratory with established relationships across urology practices nationwide. The partnership combines Valar’s computational pathology capabilities with PathNet’s existing laboratory infrastructure to support broader adoption of AI-powered diagnostics in bladder cancer care.
The Vesta portfolio uses AI to analyze pathology slides to predict outcomes and patient response to therapy in non-muscle-invasive bladder cancer cases.
“We are excited to bring Valar Labs’ Vesta portfolio to our clinical partners,” says Jason Camilletti, CEO of PathNet, in a release. “PathNet’s commitment to advanced digital pathology, combined with our long-standing relationships across major urology practices, allows us to deliver AI-driven innovation directly to the clinicians who need it most.”
AI-Powered Bladder Cancer Tools
The Vesta Bladder Risk Stratify tool provides prognostic insights for NMIBC patients, while Vesta Bladder BCGPredict focuses on predicting patient response to BCG therapy, a standard immunotherapy treatment for bladder cancer.
Both tools analyze standard pathology slides using artificial intelligence algorithms to generate clinical insights that can inform treatment decisions. The partnership aims to make these AI-powered diagnostic capabilities more accessible to urology practices through PathNet’s established laboratory network.
Valar Labs focuses on AI-powered diagnostics for oncology applications, while PathNet provides digital pathology services with emphasis on faster tissue processing and improved turnaround times for clinical results.
ID 163942834 | Bladder Cancer © Katerynakon | Dreamstime.com
